NeoMend pulls together $6M for wound healing
NeoMend, an Irvine, Calif., biomaterials company focused on wound care, raised $6 million in a third funding round, VentureWire reports (subscription required). Investors included Prospect Venture Partners, Sanderling Ventures and other unidentified venture capitalists. Four million dollars in bridge loans from Prospect and Sanderling also converted into equity.
NeoMend is developing an adhesive gel it calls Pro/PEG that can be sprayed or injected into surgical or other wounds to close them up. The company said the funding proceeds would cover the launch of its first product, which is aimed at sealing up arterial injuries.
Next Story: Galen Partners closes $250M healthcare fund
Previous Story: Tikvah Therapeutics rakes in $10M for neurological drugs
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.